Ionis Pharmaceuticals provides update on GSK IONIS-TTR Rx program
Ionis Pharma announced that GSK, which has an option to exclusively license IONIS-TTRRx, has decided not to initiate a Phase 3 outcome study, CARDIO-TTR, which was planned to evaluate IONIS-TTRRx in patients with TTR amyloid cardiomyopathy. May 26, 2016